Gilvetmab: A Novel Immunotherapy in the Fight Against Cancer
1.0 CE Credit Hour / Veterinarians & Veterinary Technicians
Overview:
Veterinary oncology has seen significant advancements in immunotherapy, offering novel treatment approaches for companion animals diagnosed with cancer. Immunotherapy aims to harness the body’s immune system to recognize and attack cancerous cells, reducing reliance on traditional treatments such as chemotherapy and radiation therapy. This lecture discusses the novel class of agents called “checkpoint inhibitors,” focusing on the first in veterinary medicine, gilvetmab.
Learning Objectives:
- Understanding the basics of immunotherapy in the fight against cancer
- Understanding checkpoint inhibitors
- Their mechanism of action
- Examples in physician-based medicine
- Challenges of this class of agents
- Gilvetmab and the data behind it in veterinary medicine
- Where we see the future of this product
- Basic knowledge behind immunotherapy
- Understanding checkpoint inhibitors
- Analyze the current data behind gilvetmab's conditional licensure.
- Apply this data to primary care and what cases may be eligible for treatment
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Dr. Craig Clifford graduated from Mississippi State University College of Veterinary Medicine and received an MS in Animal Science /Virology from the University of Delaware. After completing an internship and a medical oncology residency at the University of Pennsylvania, he became a diplomate of the American College of Veterinary Internal Medicine (Oncology) in 2003. He is a medical oncologist at Bluepearl Malvern. He is active in clinical research within a referral setting and serves as an advisory board member with industry and non-profit foundations. He has authored/co-authored over 70 papers and book chapters and is a frequent lecturer at major veterinary meetings in the USA and abroad. Dr. Clifford is a member of the Mars Veterinary Oncology Advisory Board, has served on many VCS and ACVIM committees, as well as being a member of the Oncology Pathology Working Group, and was an Examiner for the Australian Scientist’s Oncology Specialty Exam.
This course is RACE-approved for 1.0 continuing education credits hours in jurisdictions that accept RACE-approval.
This activity is sponsored by Merck.
